affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
The same operation now runs under two domains. The legacy site is still live, the new domain inherits the old contact infrastructure, and the Trustpilot review base was seeded via a promo-code review program. Here's the buyer-relevant breakdown.
Limitless Life Nootropics rebranded to Limitless Biotech in May 2026. The two storefronts share contact infrastructure (the new domain still serves the legacy `support@limitlesslifenootropics.com` address alongside `help@limitlessbiotech.com`), share owner-of-record identity, and operate from overlapping shipping origins. Catalog, pricing, and COA practices appear unchanged. The Trustpilot review base for the legacy brand was seeded via a promo-code-conditional review program, per third-party reporting.
Limitless Life Nootropics launched limitlessbiotech.com in early May 2026 while keeping the legacy limitlesslifenootropics.com domain live. The new domain currently redirects to the legacy site, and the legacy site's footer carries both brand emails side by side. There is one operation behind both names.
Three things continue uninterrupted across both domains:
Contact infrastructure. The new domain's customer-service form still routes to support@limitlesslifenootropics.com (the legacy address) alongside a new help@limitlessbiotech.com. That dual-routing is not normal for a clean break between two companies. It indicates ungroomed inheritance from one brand to the other.
Catalog and pricing. The product lineup is identical across the two storefronts. The GLP-1 mainstream (retatrutide, tirzepatide, semaglutide) plus the healing peptides (BPC-157, TB-500) ship from the same warehouse with the same per-mg pricing.
COA practices. Per-batch certificates continue to publish on flagship SKUs, typically via Janoshik Analytical, with batch IDs that resolve to the lab's own public listing. Our COA verifier works against either brand identifier.
The brand name. "Limitless Life Nootropics" is the legacy identity. "Limitless Biotech" is the new one. Both are live.
The domain. Two domains operating concurrently is unusual but not damning. Most rebrands take down the old domain or 301-redirect it. Limitless kept both pointing at the same backend.
The Trustpilot context. Mynucleus reported in May 2026 that the legacy brand's Trustpilot review base was seeded via a promo-code-conditional review program. The reviews themselves are real customers, but the program structure (discount for review) skews the rating positive. Buyers reading Trustpilot for either domain should know this.
Not a closure event. This is not the pattern that preceded the three vendors that closed in 12 months. Those closures showed COA quality collapse, regulatory action, or both. The Limitless rebrand shows neither - the catalog, COAs, and customer service all continue as before.
Worth knowing. Multi-domain operation makes it harder to track vendor history. If a buyer is researching Limitless Biotech in 2027 and missing the Limitless Life Nootropics history, they're missing two years of community signal. That's the practical buyer cost.
The pseudonym question. "Francisco D'Anconia" is a public-facing pen name borrowed from Atlas Shrugged. Many research-peptide operators use pseudonyms for regulatory reasons. The pen name itself is not a quality signal. The fact that it's consistent across both brand domains is what matters - it confirms the same operator behind both.
The Limitless Life / Limitless Biotech case is one of the cleaner examples of a research-peptide rebrand. The pattern we watch more carefully is the "alias cluster" - multiple vendor identities operated by the same owner using different contact information and pricing tiers to address different buyer segments. See our forensic alias-cluster research for the methodology and 31-vendor scan.
Same operation, two domains. Independent industry trackers (Project Biohacking, Mynucleus) and our own contact-fingerprint scan show that the new `limitlessbiotech.com` domain inherits the legacy brand's `support@limitlesslifenootropics.com` address and ownership signals. The legacy site remains live as of May 2026. Buyers ordering from either domain are buying from the same operation.
No observed change. The catalog, pricing tier, and third-party COA publication cadence (typically Janoshik Analytical) appear unchanged across the two domains. We continue to track public-test entries for both brand identifiers as the same vendor.
Reporting from Mynucleus indicates the legacy brand's Trustpilot reviews were seeded via a promo-code-conditional review program (free product or discount in exchange for a review). This is not unique to Limitless and is a common e-commerce growth tactic, but it means Trustpilot scores for this vendor should be weighted with that context.
The owner-of-record uses a public pseudonym ("Francisco D'Anconia," a character from Atlas Shrugged). Common practice in the research-peptide niche where operators value privacy for regulatory reasons. The pseudonym is consistent across both brand domains.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
